| Course | HCR 555 Pharmaceutical Safety and Risk Management |
|---|---|
| Module | Module 6 |
| Paper type | Risk-minimization plan |
| Length | About 754 words, 5 pages |
| Format | APA 7 student paper |
| School | Arizona State University |
| Program | MS in Regulatory Science |
| Updated | October 2026 |
Free sample paper for HCR 555 Module 6
Test Before the First Tablet: A Risk-Minimization Plan for Carbamazepine and HLA-B*15:02
Student Name
MS in Regulatory Science, Arizona State University
HCR 555: Pharmaceutical Safety and Risk Management
Instructor Name
Month Day, Year
Test Before the First Tablet: A Risk-Minimization Plan for Carbamazepine and HLA-B*15:02
Purpose
This plan aims to minimize the risk of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN) in patients who carry the HLA-B*15:02 allele, while preserving access to an effective, inexpensive drug for epilepsy, trigeminal neuralgia and bipolar disorder.
The Risk and the Evidence
SJS-TEN are rare but devastating reactions in which the skin and mucous membranes blister and slough; mortality for TEN is high, and survivors may be left with lasting eye and skin damage. In Han Chinese patients in Taiwan, researchers found that HLA-B*1502 was present in every patient with carbamazepine-induced SJS in their sample and in only a small share of tolerant patients (Chung et al., 2004). A prospective study then genotyped 4,877 patients in Taiwan before treatment and advised the 7.7% who carried the allele to avoid carbamazepine; none of the noncarriers who received the drug developed SJS-TEN, whereas the historical incidence predicted about ten cases (Chen et al., 2011). The allele is common in parts of East and Southeast Asia and rare in people of European or African ancestry. The Clinical Pharmacogenetics Implementation Consortium recommends that carriers not be given carbamazepine if they have not previously taken it, and notes a second allele, HLA-A*31:01, associated with milder and severe reactions in other populations (Phillips et al., 2018).
Goals and Objectives
| Goal | Objective | Metric |
|---|---|---|
| Prevent SJS-TEN in allele carriers | Genotype at-risk patients before first prescription | Percent of new at-risk starts with a result on file |
| Avoid unnecessary loss of access | Return results quickly and offer alternatives | Median days from order to result; percent of carriers given an alternative |
| Detect reactions early | Educate every patient on warning signs | Percent of patients receiving the medication guide |
| Report and learn | Report every SJS-TEN case | Number of reports and their genotype status |
Risk-Minimization Tools
1. Labeling. Keep the boxed warning recommending HLA-B*15:02 testing for patients with ancestry in populations where the allele is common, with clear advice that carriers should not start the drug unless benefits clearly outweigh risks.
2. Medication guide. Give every patient a plain-language guide, translated into the languages most common among at-risk groups, describing early signs such as fever, painful rash and mouth sores and telling patients to stop and seek care.
3. Electronic prescribing prompts. Build a hard stop into health system records that requires a genotype result, or a documented reason, before a first carbamazepine order for an at-risk patient, and preemptively store results for future prescribing.
4. Prescriber education. Short training for neurologists, psychiatrists and primary care clinicians on who to test and what to do with a positive result, including alternatives that do not share the risk.
5. Laboratory access. Contract with laboratories to return results within a few days, so that testing does not delay treatment of seizures.
6. Pharmacovigilance. Ask reporters of SJS-TEN to include genotype and ancestry, and review cases yearly to detect new at-risk groups.
These tools are labeling and communication measures. A formal Risk Evaluation and Mitigation Strategy with elements to assure safe use, such as restricted dispensing, is authorized by law when needed (21 U.S.C. § 355-1), but it would add burden to an old generic drug with many manufacturers and is not recommended unless the measures above fail.
Evaluation
Success will be measured as the proportion of at-risk patients genotyped before a first prescription, the time to results, the number of SJS-TEN cases reported each year by genotype and surveys of prescriber knowledge. A rise in cases among tested noncarriers would signal a new genetic or nongenetic risk factor.
Ethical Issues and Implications
Ethical
Testing by ancestry is imperfect, because self-reported ancestry is unreliable and many people have mixed heritage. Universal testing avoids that problem but costs more. Either approach must avoid implying that ancestry alone defines biology.
Legal
Genetic results are protected health information, and patients may worry about discrimination. The Genetic Information Nondiscrimination Act protects against discrimination in health insurance and employment but not in life or long-term care insurance, which should be explained.
Social
Access to testing varies. If results are slow or unpaid, clinicians may avoid carbamazepine altogether in Asian patients, denying an effective drug to the 90% or more who do not carry the allele.
Conclusion
Carbamazepine shows pharmacogenomics at its most useful: a single test, done once, can prevent a rare but catastrophic reaction. A plan built on labeling, education, prompts in the prescribing system and fast testing can deliver that protection without turning an inexpensive drug into a restricted one.
References
Chen, P., Lin, J.-J., Lu, C.-S., Ong, C.-T., Hsieh, P. F., Yang, C.-C., Tai, C.-T., Wu, S.-L., Lu, C.-H., Hsu, Y.-C., Yu, H.-Y., Ro, L.-S., Lu, C.-T., Chu, C.-C., Tsai, J.-J., Su, Y.-H., Lan, S.-H., Sung, S.-F., Lin, S.-Y., . . . Shen, C.-Y. (2011). Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. New England Journal of Medicine, 364(12), 1126-1133. https://doi.org/10.1056/NEJMoa1009717
Chung, W.-H., Hung, S.-I., Hong, H.-S., Hsih, M.-S., Yang, L.-C., Ho, H.-C., Wu, J.-Y., & Chen, Y.-T. (2004). A marker for Stevens-Johnson syndrome. Nature, 428(6982), 486. https://doi.org/10.1038/428486a
Phillips, E. J., Sukasem, C., Whirl-Carrillo, M., Müller, D. J., Dunnenberger, H. M., Chantratita, W., Goldspiel, B., Chen, Y.-T., Carleton, B. C., George, A. L., Jr., Mushiroda, T., Klein, T., Gammal, R. S., & Pirmohamed, M. (2018). Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update. Clinical Pharmacology & Therapeutics, 103(4), 574-581. https://doi.org/10.1002/cpt.1004
Risk evaluation and mitigation strategies, 21 U.S.C. § 355-1 (2024).
What the HCR 555 Module 6 instructions ask for
Week 6 of HCR 555 turns to pharmacogenomics, personalized medication and risk management, and Assignment 5 joins them. The syllabus asks you to develop a risk-mitigation plan for a pharmaceutical product that considers how genetics affects drug response and personalized medication, and to discuss the ethical issues and implications of pharmacogenomics. A strong choice is a drug with a well-documented gene-drug interaction and an existing FDA labeling statement, such as carbamazepine and HLA-B*15:02, clopidogrel and CYP2C19 or abacavir and HLA-B*57:01, because the evidence and regulatory history are public. The plan itself should look like a plan: the risk and its evidence, goals, tools, how success will be measured and who acts. The ELSI framework and the course's grading for content and mechanics apply as in the earlier papers, for 100 points.
How the HCR 555 Module 6 example is put together
The sample states the plan's purpose in one sentence that balances safety with access. The evidence section moves from the original genetic association to a prospective screening study with its numbers and then to the current clinical guideline. Goals, objectives and metrics are set out together in a table. Six risk-minimization tools follow as a numbered list, with a paragraph explaining why a formal REMS with restricted distribution is not recommended for an old generic drug. An evaluation section defines what success and failure would look like. The ethical, legal and social discussion addresses ancestry-based testing, genetic privacy and access, and the conclusion restates why one test can justify the whole plan.
Reading the HCR 555 Module 6 grading rubric
The risk-minimization plan is graded on content and mechanics like the other HCR 555 papers. Content marks reward a well-chosen gene-drug pair with accurate evidence, goals and measurable objectives, tools proportionate to the risk and suited to how the drug is actually prescribed, an evaluation plan with metrics and an ELSI discussion of pharmacogenomics that goes beyond privacy to cover ancestry, access and equity. Points are lost when the plan is a description of pharmacogenomics without a plan, when tools are listed without saying who does what, when evidence is overstated and when the ethical discussion is generic. Readers in a regulatory program also look for an understanding of when a formal REMS is warranted and when labeling and education are enough.
HCR 555 Module 6 help: mistakes that cost marks
Pick a gene-drug pair with a CPIC guideline and an FDA labeling statement, so the evidence is ready. Write the purpose to balance safety and access. Put goals, objectives and metrics in one table. Choose tools that fit the drug's real use, and say why you did or did not choose a REMS. Define what would show the plan is failing. In the ethics section, discuss how patients are selected for testing, not only data privacy. If you are deciding between two gene-drug pairs, the desk can help you choose the one with stronger public evidence. Before submitting, confirm that every tool in your plan names who carries it out.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official Arizona State University document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.
More HCR 555 and MS in Regulatory Science sample papers
- HCR 555 Module 1: Assignment 1: Drug Development From Bench to Market
- HCR 555 Module 2: Assignment 2: Risk-Benefit Analysis of Two Drugs
- HCR 555 Module 3: Assignment 3: Safety Monitoring, Reporting and Recalls
- HCR 555 Module 5: Assignment 4: Globalization, Off-Label Use, Biologics and Counterfeits
- HCR 563 Module 5: Assignment 3: Annotated Bibliography on Decentralized Trials
- HCR 544 Module 7: Food Safety Individual Project Paper
- HCR 576 Module 1: Paper: Product Profile for a Drug Under Development
- HCR 579 Module 7: Ethical Paper: Precision Medicine
HCR 555 Module 6 questions, answered
Where can I find a free HCR 555 Module 6 sample paper?
The page above holds the full Assignment 5 risk-minimization plan for carbamazepine and the HLA-B*15:02 allele.
Why test for HLA-B*15:02 before carbamazepine?
People who carry the allele are far more likely to develop the blistering skin reactions SJS and TEN, and a Taiwan screening program avoided the cases history predicted.
What is a risk-minimization plan?
A plan that states a drug's risk, sets goals and uses tools such as labeling, education and prescribing controls, with metrics to judge success.
When does FDA require a REMS?
When labeling alone is not enough to ensure a drug's benefits outweigh a serious risk; some REMS add elements to assure safe use.
What ethical issues does pharmacogenomic testing raise?
Testing by ancestry, genetic privacy and discrimination and unequal access to testing and to the drug.